J9321 Injection epcoritamab-bysp 0.16 milligrams
Also known as: epcoritamab, Epkinly
Injection of epcoritamab-bysp, 0.16 milligram. A bispecific B-cell engagement antibody (CD3 x CD20) for B-cell lymphomas.
In Plain Language
lymphoma immune injection; T-cell engaging therapy
Clinical Context
Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engaging T-cells to CD20-positive B-cell lymphomas.
RVU Information
CPT J9321 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9321?
CPT J9321 (Injection epcoritamab-bysp 0.16 milligrams) is a J Codes (Drugs) code. Injection of epcoritamab-bysp, 0.16 milligram. A bispecific B-cell engagement antibody (CD3 x CD20) for B-cell lymphomas.
How is J9321 administered?
CPT J9321 is administered by a healthcare provider, typically via injection or infusion. Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engaging T-cells to CD20-positive B-cell lymphomas. It is used by Oncology, Hematology, Immunology.
When is CPT J9321 used?
Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engaging T-cells to CD20-positive B-cell lymphomas.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.